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Abstract
Background: A nascent HIV epidemic and high prevalence of risky drug practices were detected among injecting
drug users (IDUs) in Kabul, Afghanistan from 2005-2006. We assessed prevalence of HIV, hepatitis C virus (HCV),
hepatitis B surface antigen (HBsAg), syphilis, and needle and syringe program (NSP) use among this population.
Methods: IDUs were recruited between June, 2007 and March, 2009 and completed questionnaires and rapid
testing for HIV, HCV, HBsAg, and syphilis; positive samples received confirmatory testing. Logistic regression was
used to identify correlates of HIV, HCV, and current NSP use.
Results: Of 483 participants, all were male and median age, age at first injection, and duration of injection were 28, 24,
and 2.0 years, respectively. One-fifth (23.0%) had initiated injecting within the last year. Reported risky injecting practices
included ever sharing needles/syringes (16.9%) or other injecting equipment (38.4%). Prevalence of HIV, HCV Ab, HBSAg,
and syphilis was 2.1% (95% CI: 1.0-3.8), 36.1% (95% CI: 31.8-40.4), 4.6% (95% CI: 2.9-6.9), and 1.2% (95% CI: 0.5-2.7),
respectively. HIV and HCV infection were both independently associated with sharing needles/syringes (AOR = 5.96,
95% CI: 1.58 - 22.38 and AOR = 2.33, 95% CI: 1.38 - 3.95, respectively). Approximately half (53.8%) of the participants
were using NSP services at time of enrollment and 51.3% reported receiving syringes from NSPs in the last three
months. Current NSP use was associated with initiating drug use with injecting (AOR = 2.58, 95% CI: 1.22 - 5.44), sharing
injecting equipment in the last three months (AOR = 1.79, 95% CI: 1.16 - 2.77), prior incarceration (AOR = 1.57, 95% CI:
1.06 - 2.32), and greater daily frequency of injecting (AOR = 1.40 injections daily, 95% CI: 1.08 - 1.82).
Conclusions: HIV and HCV prevalence appear stable among Kabul IDUs, though the substantial number having
recently initiated injecting raises concern that transmission risk may increase over time. Harm reduction
programming appears to be reaching high-risk drug user populations; however, monitoring is warranted to
determine efficacy of prevention programming in this dynamic environment.
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Introduction
Central Asia has been identified as a region of concern
for expanding human immunodeficiency virus (HIV)
epidemics largely driven by injecting drug use [1,2].
Increased rates of drug use, particularly injecting use, in
this region have been attributed to multiple factors,
including high unemployment, political instability, and,
predominantly, an increasing opiate supply from Afgha-
nistan [2,3]. Though Afghanistan’sr o l ea sa no p i u m
producer is widely known, consumption within the
country has received relatively less attention [4,5]. Based
on a 2009 national survey, approximately 2.7% of the
adult population is estimated to use opiates, and both
smoking and injection of heroin are believed to be
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in urban areas, particularly injecting use, where 20% of
urban heroin users are estimated to inject [5]. A 2007
mapping study estimated a total injecting drug user
(IDU) population of 1465 across three Afghan cities,
with 1261 in Kabul city [6].
In 2005-2006, we conducted a cross-sectional assess-
ment of the seroprevalence of HIV and viral hepatitis
among 464 Kabul IDUs [7]. Although HIV prevalence
was low at 3.1%, HCV prevalence was higher at 36%.
Levels of lifetime risk behaviors were high, reflected by
50.4% having ever shared needles or syringes, and harm
reduction program use was low, with only one partici-
pant reporting needle and syringe collection and distri-
bution program (NSP) use [7,8]. Since the 2006 study,
drug use patterns and the number of drug users have
changed, with the numbers of drug users, injectors, and
those using heroin as their drug of choice increasing in
2009 [5]. In this interval, the number and range of harm
reduction services have also expanded, particularly in
Kabul. In 2009, HIV prevalence among IDUs in Kabul
was 3%, suggesting some stability in the environment
since 2006 [7,9]. This biobehavioral survey also noted
that 98% of Kabul IDUs reported using a sterile needle
at their last injection; however, the national drug use
survey performed in 2009 indicated that 87% of IDUs
reported lifetime needle sharing and that 60% reported
their syringes had been used by between 2 and 5 people
prior to their personal use [5,9]. These data appear con-
tradictory and clarification of injecting behaviors is
needed, for which serial prevalence data may provide
some objective measures.
The purpose of this manuscript is to describe the pre-
valence and correlates of HIV, syphilis, and hepatitis B
and C and harm reduction program use among IDUs
entering a cohort recruited in Kabul, Afghanistan
between June, 2007 and March, 2009.
Methods
Setting
Kabul is the capital and largest city in Afghanistan, esti-
mated to have a population of 2.8 million in 2008 [10].
Kabul also has among the highest density of opium and
heroin users and IDUs nationally [5]. At the beginning
of the recruitment period, three NSPs were operating as
were two addiction treatment programs available at no
cost. No methadone maintenance programs were oper-
ating during the enrollment period.
Participant Eligibility & Recruitment
IDUs aged 18 years or greater who had injected within
the last 30 days and residing in Kabul were eligible for
entry. Potential participants were recruited at sites
within Kabul city frequented by drug users and through
NSPs by trained study staff; no set sample size was
employed for recruitment from either site. Recruitment
at sites frequented by drug users was done as a variant
on time-location sampling, as study staff were present
for enrollment at each of four to five sites based on the
number of potential participants present at those sites.
Site selection was re-evaluated monthly as congregation
sites frequently shifted for various reasons, such as
police harassment. Further, study staff would regularly
visit pharmacies throughout the city and inquire with
harm reduction outreach workers and participants
regarding new sites for IDU congregation. Sites were
distributed throughout Kabul, but, for the majority of
the enrollment period, were largely concentrated in the
western sections of the city, consistent with reported
and confirmed IDU presence throughout the study per-
iod. Potential participants were also approached at drop-
in centers for the three harm reduction programs in
Kabul; study staff enrolled or performed follow-up inter-
views for participants recruited at these sites one after-
noon each week throughout the study. For this
convenience sample, IDUs interested in participation
accompanied staff to a private room at the harm reduc-
tion center or to the study office for explanation of the
study and provision of informed consent. Due to low lit-
eracy rates, potential participants were asked a series of
questions following presentation of the consent by study
staff to ensure comprehension; fingerprint was provided
in lieu of signature per participant preference. Potential
participants declining entry were not enumerated nor
was any information collected from these individuals.
The institutional review boards of the Afghan Ministry
of Public Health, University of California San Diego, and
Columbia University approved the protocol.
Measurement of variables and outcomes of interest
The questionnaire instrument assessed sociodemo-
graphics, travel, incarceration and medical histories,
drug use and sexual behaviors, and knowledge of infec-
tion transmission and prevention. Drug use behaviors of
interest included sharing needles/syringes ever and in
the last three months, sharing injecting “works” (e.g.
cookers, cotton) ever and in the last three months, dura-
tion of injecting, injecting while incarcerated, aspirating
and re-injecting blood (khoon bozee), and receiving
assistance with injecting. Assistance with injecting was
assessed with the question of whether anyone, including
a group leader, had injected a given participant. Transi-
tion from smoking to injecting opiates or other sub-
stances was also specifically queried, as was geographic
location of injecting initiation.
Sexual risk behaviors of interest were having used a
condom at any sexual encounter, ever having sex with
men or boys, and having patronized a female sex worker
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routes of transmission were also assessed, such as
receipt of therapeutic injections.
The outcomes of interest were prevalence of HIV,
syphilis, and hepatitis B and C infection and reported
NSP program use. NSP program use at enrollment was
defined as both current stated participation and report-
ing currently receiving syringes from a program.
Procedures
Study staff were Afghan men who had worked with drug
users through either harm reduction programs or
through medical practice and included at least one phy-
sician at all times. Staff were trained in human subjects
research, voluntary counseling and testing practices,
phlebotomy and serum preparation, and questionnaire
administration. The senior study managers throughout
the project, both Afghan physician (MRS and AN), pro-
vided quality assurance in the field through instrument
completion checks and direct observation.
Following informed consent, participants completed
the interviewer-administered questionnaire, received
pre-test counseling, and underwent whole blood rapid
testing for HIV-1, syphilis, hepatitis B surface antigen
(HBsAg), and hepatitis C antibody (HCV Ab) (all rapid
tests from SD Bioline, Standard Diagnostics, Kyonggi-
do, Korea). Participants with reactive rapid test results
underwent intravenous sampling for confirmatory test-
ing. Participants then received post-test counseling,
hepatitis B vaccine as needed, and were scheduled for
health education classes and follow-up tests results, as
indicated. All participants completed four health educa-
tion classes covering injection and sexual risk reduction,
abscess prevention, and nutrition and hygiene. Basic
hygiene supplies (e.g. soap, razor, toothbrush) were pro-
vided upon completion of the classes (value US$4), not
advertised at the time of recruitment to avoid coercion.
Laboratory Testing
All confirmatory testing was performed at the Afghan
Public Health Institute laboratory in Kabul. Samples
reactive for HIV on rapid test received Western blot
confirmation (HIV Blot 2.2, Genelabs, Singapore). For
hepatitis C, polymerase chain reaction (PCR) (Amplicor,
Roche Diagnostics, Mannheim, Germany) was used to
confirm infection with reflex RIBA (recombinant immu-
noblot assay) (Chiron RIBA 3.0 SIA, Chiron Company,
Emeryville, California) employed for samples with no
detectable virus. HBV confirmation was performed with
PCR (Amplicor, Roche Diagnostics, Mannheim, Ger-
many) for reactive specimens. Syphilis infection was
confirmed with Treponema pallidum plasma agglutinin
assay (TPPA) (Fujirebio, Wilmington, DE, USA), with
rapid plasma reagin (RPR) titre (Inverness Medical,
Princeton, NJ, USA) for guidance of clinical decision-
making. Participants were encouraged to follow up for
confirmatory tests results but were not actively sought
to preserve confidentiality.
Treatment referrals were provided for participants
with confirmed cases of HIV, hepatitis B, and/or C
receiving test results to sites within the public health
system providing antiretroviral therapy and hepatitis
supportive care. Confirmed syphilis cases with RPR
titre≥1:4 were offered treatment with intramuscular
benazathine penicillin per international treatment guide-
lines [11].
Statistical Analysis
The target sample size for cohort entry was 450, suffi-
cient to detect at least a 16% difference in needle shar-
ing over time with 80% power (two-sided alpha = 0.05).
Descriptive statistics for the study population were gen-
erated. Prevalence and confidence intervals for each
infection were calculated with Poisson or binomial dis-
tribution as appropriate. Prevalence of NSP use at base-
line was measured with simple proportions.
Univariable logistic regression was performed to iden-
tify potential associations between outcomes of interest
and select demographic and risk behavior variables.
Variables were entered into a multiple model if they
were associated at the 10% level in univariable analysis
or were considered of epidemiologic significance; entry
into the final model was determined by likelihood ratio
test at a significance level <0.10. All analysis was per-
formed with Stata Version 10.0 (Stata Corporation, Col-
lege Station, Texas).
Results
Participant and Drug Use Characteristics
There were 483 participants recruited into the cohort
over a period of 18 months. Demographic and injecting
risk behavior characteristics are reported in Table 1.
Briefly, all participants were male and were living in
Kabul, with most living in districts 3 (37.1%), 5 (11.7%),
13 (11.5%), 1 (10.2%), 6 (6.9%), 8 (6.3%), and 2 (6.0%) of
the 17 city districts. Most were Afghan nationality and
had lived outside Afghanistan in the last 5 years. The
living situations of participants at time of cohort entry
were living with immediate (40.2%) or extended (2.5%)
family, other drug users (31.0%), or were homeless
(22.5%).
Heroin mixed with avil (76.8%) or with water or
lemon juice (22.3%) were the most frequent drug pre-
parations reportedly used in the month prior to enroll-
ment. Use of other pharmaceutical preparations for
injection was exceedingly rare, as only five participants
mentioned using benzodiazepines or phenobarbital in
combination with heroin and no participants mentioned
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Other injecting risk behaviors, including lifetime and
recent needle/syringe and injecting equipment sharing
and aspirating and re-injecting blood (khoon bozee),
were common (Table 1). Generally, Afghanistan was the
site for injecting initiation although about one-third
initiated injecting as a refugee.
Prevalence and Correlates of Infections
Prevalence of HIV, HCV Ab, HBV, and syphilis was
2.1% (CI: 1.0-3.8), 36.1% (CI: 31.8-40.4), 4.6% (CI: 2.9-
6.9), and 1.2%,(CI: 0.5-2.7), respectively. Of those who
were HIV-infected, 80% were co-infected with HCV. In
logistic regression analysis, HIV infection was signifi-
cantly associated with ever sharing needles/syringes and
marginally associated with initiating injecting outside
Afghanistan (Table 2). HCV Ab was independently asso-
ciated with initiating injecting outside Afghanistan, ever
having an abscess, ever sharing needles and syringes,
frequency of daily injection, and duration of injecting
use in multivariable logistic regression (Table 2). HBV
infection was independently positively associated with
daily income and negatively associated with current nee-
dle and syringe program (NSP) use (Table 2).
Prevalence and Correlates of NSP Service Use
Approximately half (53.8%) of the participants were
using harm reduction services at time of enrollment and
51.3% reported receiving syringes from such a program
in the last three months. HIV (1.9 vs. 2.3%, p = 0.82)
and HCV (35.0% vs. 37.4%, p = 0.59) prevalence among
NSP users was not significantly different than for non-
users; age, civil status, educational level, and being
homeless were also not significantly different between
the groups. NSP use at enrollment was associated with
prior incarceration, initiating drug use with injecting,
frequency of daily injection, sharing of injecting works
i nt h ep r i o rt h r e em o n t h s ,a n dm a r g i n a l l yw i t hb e i n g
homeless and receipt of prior drug treatment (Table 3).
Living outside the country in the last five years and per-
ceiving an urgent need for treatment were negatively
associated with NSP use at enrollment in univariable
logistic regression (Table 3). In multivariable logistic
regression, initiating drug use with injecting, sharing
Table 1 Demographic and key risk behavior
characteristics of male injecting drug users enrolled into
a longitudinal cohort study in Kabul, Afghanistan
(N = 483)
Continuous Variables Mean Median IQR
Age (years) 29.6 28 24-33
Level of education (years) 5.3 5 0-7
Age initiated injecting (years) 25.8 24 21 - 29
Duration of injecting (years) 4.0 2 1 - 6
Number of daily injections 5.7 6 5 - 6
Dichotomous Variables N %
Ever married 224 46.4
Born in Afghanistan 418 87.1
Lived outside Afghanistan in last 5 years 310 64.7
Employed at enrollment 56 11.7
Prior incarceration 302 63.1
Initiated drug use with injecting 39 8.1
Initiated injecting in the last year 111 23.0
Initiated injection inside Afghanistan 321 66.5
Ever shared needles/syringes 81 16.9
Shared needles/syringes in last 3 months 31 6.4
Ever shared injecting equipment 189 38.4
Shared injecting equipment in last 3 months 132 27.3
Ever inject/re-aspirate blood (khoon bozee) 337 70.2
Prior addiction treatment 70 14.6
Ever paid woman for sex* 177 40.4
Ever had sex with another male* 49 11.1
Ever used condom* 49 11.1
*Of 443 participants ever reporting previous sexual activity.
N = Number
IQR- Interquartile Range
Table 2 Variables independently associated with HIV and
hepatitis B and C infection in logistic regression analysis
among a cohort of male injecting drug users in Kabul,
Afghanistan (N = 483)
Variable Adjusted Odds
Ratio
95% CI
HIV:
Ever share needles or syringes 5.96 1.58 -
22.38
Initiated injecting outside
Afghanistan*
3.41 0.83 -
14.27
Hepatitis B Virus:
Daily income 1.01 1.00 - 1.01
Current needle and syringe program
use
0.36 0.14 - 0.94
Hepatitis C Virus:
Ever have abscess at injecting site 2.22 1.33 - 3.70
Ever share needles or syringes 2.33 1.38 - 3.95
Initiated injecting outside
Afghanistan
1.95 1.26 - 3.04
Frequency daily injections (#
injections)
1.47 1.11 - 1.94
Duration of injecting (per year) 1.05 1.00 - 1.10
Age (per year) 1.04 1.01 - 1.07
*Marginal significance (p = 0.087)
Most parsimonious models displayed.
CI = Confidence Interval
N = Number
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tion, and greater frequency of daily injecting were inde-
pendently associated with NSP use. Negative
associations persisted for having lived outside the coun-
try in the last five years and a perceived great need for
treatment (Table 3).
Discussion
The HIV, HCV, and HBV prevalence detected among
Kabul IDUs from 2007 to 2009 was not substantially dif-
ferent from prevalence estimates obtained in 2006 [7].
Though factors believed to predispose to a rapid epi-
demic, such as poverty, unemployment, and insecurity
have been consistently present, the explosive increase in
HIV prevalence noted between annual cross-sectional
studies in Pakistan and other settings has not yet
occurred [12-14].
The association between HIV and HCV and lifetime
needle or syringe sharing is consistent with 2006 find-
ings and potentially indicates a sustained level of risk
behavior among the population. However, reported
recent sharing of either needles/syringes or injecting
works were not associated with either infection. The
reported levels of lifetime and recent sharing among
Kabul IDUs in 2006 were much higher, as 50.4%
reported ever sharing needles or syringes and 31%
reported sharing injecting equipment in the six months
prior to enrollment [7,15]. We hypothesize that harm
reduction service expansion and inclusion of field-based
NSP services has both decreased sharing and increased
HIV transmission knowledge. However, the large
decrease in reported lifetime sharing may indicate also
that sharing is becoming a stigmatized behavior and is
subsequently under-reported. The national drug use sur-
vey from 2009 reported lifetime needle sharing of 87%
among IDUs; this survey included rural areas and noted
a concentration of injecting in the southern provinces
[5]. Few harm reduction programs operate in these pro-
vinces, where the population is predominantly rural,
limiting the ability to disseminate information on the
dangers of needle sharing. Since needle and syringe
sharing remained strongly associated with prevalent HIV
and HCV, there remains room for improvement in
terms of harm reduction expansion in Kabul.
Initiating injecting outside Afghanistan was also asso-
ciated with both HIV and HCV infection, likely reflect-
ing increased likelihood of transmission in neighboring
countries with higher HCV and HIV prevalence (e.g.
Iran, Pakistan) [13,16]. The 2005 Kabul study did not
assess where drug use and injecting were initiated,
Table 3 Variables associated with needle and syringe program (NSP) use at enrollment among male IDUs in Kabul,
Afghanistan in univariable and multivariable logistic regression analysis (N = 483)
NSP Users
(N = 258)
NSP Non-Users
(N = 222)
Variable Mean, SD Mean, SD OR, 95% CI
Frequency of daily injection 5.78+0.70 5.55+0.94 1.43, 1.12 - 1.82
N, % N, %
Lived outside last 5 years 156, 60.5% 154, 69.7% 0.66, 0.45 - 0.97
Prior incarceration 174, 67.4% 128, 57.9% 1.51, 1.04 - 2.19
Share injecting works last 3 mos 83, 32.2% 49, 22.1% 1.67, 1.11 - 2.53
Initiate drug use with injecting 28, 10.9% 11, 5.0% 2.34, 1.14 - 4.83
Perceived need for addiction therapy 243, 94.9% 219, 99.1% 0.17, 0.04 - 0.76
Receipt of prior addiction treatment* 45, 17.4% 25, 11.3% 1.66, 0.98 - 2.82
Homeless at enrollment* 66, 25.6% 42, 18.9% 1.47, 0.95 - 2.28
Multivariable Model: AOR 95% CI
Initiated drug use with injecting 2.58 1.22 - 5.44
Shared injecting works in last 3 months 1.79 1.16 - 2.77
Prior incarceration 1.57 1.06 - 2.32
Frequency of daily injection 1.40 1.08 - 1.82
Lived outside Afghanistan in the last 5 years 0.61 0.41 - 0.91
Perceived need for addiction treatment 0.15 0.03 - 0.70
AOR = Adjusted Odds Ratio
CI = confidence interval
N = number
OR = odds ratio
SD = Standard Deviation
*marginal significance (p = 0.057 - 0.082)
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outside Afghanistan [17]. As Afghans living as refugees
may not have the same access to harm reduction/NSP
services in countries of refuge, sharing needles and syr-
inges may have been more likely, as observed in Iran
[17].
HCV was associated with history of injection site
abscess, potentially reflecting rushed injecting which
m a yb eap r o x ym e a s u r ef o rs h a r i n go fe q u i p m e n t
[18,19]. In formative work, IDUs stated that relative
speed of administration and ability to conceal use, parti-
cularly from police, were possible reasons for initiating
injecting [20]. This same rationale may exist for rushed
injecting. Having had an abscess at the injection site
within the last year was associated with HCV antibody
among IDUs in the United Kingdom in a cross-sectional
study, [21] but a similar association was not observed in
a Canadian study [19].
HBV infection was not associated with sharing nee-
dles/syringes or injecting in prison, as in 2006, but was
negatively associated with current NSP use. As HIV and
HCV were not associated with NSP use, it seems less
likely that this may be a proxy for fewer risky sharing
behaviors. However, the recent expansion of NSPs in
Kabul and the greater virulence and ease of transmission
associated with HBV may provide an earlier sign of
positive behavior change associated with NSP use; forth-
coming incidence data will be assessed for impact of
NSP use on HBV and other infection incidence over
time.
There was higher reported lifetime use of harm reduc-
tion programs, specifically NSP services, than measured
in the 2006 study. As data presented here and in 2006
are cross-sectional and utilized convenience sampling,
some of this difference may be attributed to undersam-
pling NSP users in 2006 or oversampling this group
during cohort recruitment. However, an increased num-
ber of harm reduction programs and introduction of
primary exchange services in the field, now the pre-
ferred method for NSP delivery, have debuted and may
contribute to this change [22].
Current NSP users represent IDUs who, in many
respects, are at greater risk for blood-borne infection
due to initiating drug use with injecting, recent sharing
of injecting equipment, and more frequent injecting
daily. That IDUs using NSP services are more likely to
have risky injecting practices has been noted in other
settings, such as the United Kingdom and Canada
[23-25]. The data indicate that these services are reach-
ing their target clientele; however, service delivery in
this setting is a work in progress and efficacy remains
an open question. NSP users were substantially less
likely to perceive great need for treatment, potentially
indicating NSP use is an entrée to addiction treatment.
This relationship has been established in other settings
and several harm reduction programs in Kabul have
incorporated abstinence-based treatment programs
[26,27]. As opioid substitution treatment (OST) is scaled
up, harm reduction programs will need to ensure that
linkages remain in place to treatment [26-28]. Further,
programs should incorporate a low threshold model
consistent with harm reduction rather than an absti-
nence based approach which has unrealistic expectations
regarding the recovery process. The negative association
between NSP use and having lived outside the country
in the last five years may represent difficulties experi-
enced by recently-repatriated IDUs in accessing services
of which they may not be aware.
This study has several limitations. Participants were
enrolled over a lengthy period by convenience sampling
and may not be representative of IDUs in Kabul.
Further, no data were recorded on those ineligible or
declining entry, potentially leading to under-representa-
tion of hidden or isolated groups. We elected not to use
respondent-driven sampling or other chain-referral
methods in this setting for two reasons. First, based on
qualitative work preceding co h o r te n r o l l m e n ti nK a b u l ,
drug users perceive that injection drug use results in
better services and greater opportunities for compensa-
tion [20]. Memorably, we were informed by one partici-
pant that press photographers would pay IDUs to be
photographed or videotaped while injecting. By choosing
and compensating seeds and recruits, we were con-
cerned that drug users might inadvertently initiate
injecting due to compensation, which may weigh on
perceived ability to meet basic needs in this impover-
ished setting [29]. Similar concerns have been voiced by
researchers in Lebanon [30]. We did not monetarily
compensate our participants and also ensured that med-
ical care, including VCT services and naloxone, were
available to non-participants upon request. Next, in
insecure environments where frequent migration outside
and within the city occurs, networks are transient and
assignment of seeds may not guarantee recruit deriva-
tion from the same network. This network fragility may
then prompt “seeds” to recruit IDUs unknown to them,
compromising the validity of RDS and increasing risk
for coercive practices between seed and recruiter.
Socially desirable response may have occurred, parti-
cularly with sensitive behaviors; we attempted to reduce
this through staff familiar to the participant population
and providing choice as to location of the study inter-
view. Though audio computer-assisted survey interview-
ing has been noted to improve self-reporting among
IDUs, this technology was not financially possible or fea-
sible in this environment where there was often no
power and the team was largely field-based [31]. HIV-
related analyses were underpowered due to low
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were no female IDUs enrolled, precluding characteriza-
tion. Female IDUs exist in Kabul but access to this hid-
den group has been elusive as the few women using
harm reduction services are not injectors and require
home visits due to cultural proscriptions.
Conclusions
In summary, both injecting drug use and NSP utilization
appear to be increasing in Kabul, Afghanistan. Injecting
has become an accepted and popular route of drug
administration, tied to many factors, with the ready
availability of heroin among the most important. The
apparent stability of HIV and HCV prevalence between
an earlier study and this cohort at baseline may be offset
by influx of new injectors and environmental factors
favoring an explosive epidemic. Harm reduction pro-
gram and NSP use appear acceptable and efforts to
improve service quality and scale up effective interven-
tions, particularly OST, are urgently needed.
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